

## Coverage Determination Request Form - Vaccines (Medicare Part B vs. Part D Coverage)

This request is:  Expedited\* (Urgent)  Standard (Non-Urgent)

\*Expedited means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

Please note: All information below is required to process this request. Any information that is incomplete or illegible will delay the review process.

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Member Insurance ID #:			NPI # :		Specialty:
Date of Birth:			Office Phone:		
Member Phone:			Office Fax:		
Member Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:

Medication Information (required)	
Indicate Medication Requested: ( <b>NOTE:</b> Drugs below are a representative list, only. See plan formulary to verify coverage status.)	
<input type="checkbox"/> Hepatitis A (Inact)-Hep B (Recomb) (TWINRIX) <input type="checkbox"/> Hepatitis B Vaccine (Recombinant) (ENERGIX-B) <input type="checkbox"/> Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) <input type="checkbox"/> Rabies Immune Globulin (Human) (HYPERRAB S/D) <input type="checkbox"/> Rabies Immune Globulin (Human) (IMOGAM RABIES-HT) <input type="checkbox"/> Rabies Vaccine, PCEC (RABAVERT)	<input type="checkbox"/> Rabies Virus Vaccine, HDC [IMOVAX RABIES (H.D.C.V.)] <input type="checkbox"/> Tet Tox-Diph-Acell Pertuss Adsorbed (ADACEL / BOOSTRIX) <input type="checkbox"/> Tetanus-Diphtheria Toxoids (Td) <input type="checkbox"/> Tetanus Vaccine, (PEDIARIX) <input type="checkbox"/> Tetanus Vaccine, TENIVAC <input type="checkbox"/> other _____
Strength:	Dosage Form:
Quantity Prescribed:	Directions for Use:

**B vs. D Primary Billing Determination (required)**

Requests for ENERGIX-B, RECOMBIVAX HB, and TWINRIX:

**Patient must meet ONE (1) of the following:**

**Individual is at high risk for contracting Hepatitis B (defined as):** ESRD Patients, HEMOPHILIACS who receive Factor VIII or IX concentrates, persons with Medicare in institutions for the mentally disabled, other persons who live in the same household as a Hepatitis B Virus (HBV) carrier, homosexual men, illegal injectable users, persons diagnosed with diabetes mellitus. **(Bill to Medicare Part B)**

**OR**  **Individual is at medium risk for contracting Hepatitis B (defined as):** Staff who work in institutions for the mentally disabled, health care professionals who have frequent contact with blood or blood-derived body fluids during routine work. **(Bill to Medicare Part B)**

**OR**  **Individual is not at high or medium risk of contracting Hepatitis B (as defined above).**  
**(Complete Part D Coverage Determination Criteria section below)**

Requests for ADACEL, BOOSTRIX, HYPERRAB S/D, IMOGAM RABIES-HT, IMOVAX RABIES (H.D.C.V.), PEDIARIX, RABAVERT, TENIVAC, and Tetanus-Diphtheria Toxoids (Td):

**Patient must meet ONE (1) of the following:**

Vaccine administration is directly related to the treatment of an injury or direct exposure to a disease or condition (**post-exposure prophylaxis**) **(Bill to Medicare Part B)**

**OR**  Vaccine administration is a **preventative immunization** **(Complete Part D Coverage Determination Criteria section below)**

**Part D Coverage Determination Criteria (required)**

The following requirements need to be met before this drug can be covered by the Part D plan. These requirements have been approved by the Centers for Medicare and Medicaid Services (CMS), but you may ask us for an exception if you believe one or more of these requirements should be waived.

**Which condition is the drug being used for?**

Indicate diagnosis: \_\_\_\_\_ ICD-10 Code (s): \_\_\_\_\_

**Please Note:** This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is *either*:

- Approved by the Food and Drug Administration (FDA) – that is, that the FDA has approved the drug for the diagnosis or condition for which it is being prescribed.
- Supported by any of the following reference books – American Hospital Formulary Service Drug Information, the DRUGDEX Information System, and/or the USPDI or its successor.

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other pertinent information the physician feels is important to this review?**  Yes  No (If yes, please explain, below)

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Exception Requests (optional)**

**Do you believe one or more of the prior authorization requirements should be waived?**  Yes  No

If yes, you must provide a statement explaining the medical reason why the exception should be approved.

Would this medication likely be the most effective option for this patient?  Yes  No

(If yes, please explain why, below)

---

---

---

If the patient is currently using this medication, would changing the current regimen likely result in adverse effects for the patient?  Yes  No (If yes, please explain why, below)

---

---

---

### Submission Information (required)

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Please Note:

- This request may be denied or dismissed unless all required information is received.
- Your office will receive a response via fax.
- For urgent requests, please call (866) 270-3877.
- For real time submission 24/7 please visit the secure prescriber portal on our plan's website for the appropriate form and instructions on how to submit your request.

**Authorization Period:** 1 Year - subject to formulary change and member eligibility.

**\*\*PLEASE FAX COMPLETED FORM TO: 855-668-8552\*\***

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). This message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to civil or criminal penalties. If you received this transmission in error, please notify us immediately by telephone at (866) 270-3877.